The US FDA’s Antimicrobial Drugs Advisory Committee on Aug. 7 strongly supported approval of Insmed Inc.’s amikacin liposome inhalation suspension (ALIS) in nontubercuolous mycobacterial (NTM) lung disease but for a narrower indication than that sought by the company.
The panel voted 12-2 that the efficacy and safety data support use in adults with NTM caused by Mycobacterium avium...





